Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 7, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 5, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$68.48 Published $81.26 Target $59.63 Window close $71.00 Peak
$64.54 – $68.45Entry zone — fair-value band
$68.48Published — price the day we called it
$81.26Target — the price the thesis aimed for
$71.00Peak — highest point inside the window, not a realized return
$59.63Window close — end-of-window price, context only

What happened

Partial

Reached 19% of the predicted growth at its peak, without hitting the target.

Peak price
$71.00
peak on July 25, 2025 — not a realized return
Peak gain
+3.7%
peak, from the publication price
Window close
$59.63
end-of-window price, context only
Days to target
—
Window
July 7, 2025 – October 5, 2025

The thesis — published July 7, 2025

Predicted growth
+20%
over the measurement window
Target price
$81.26
the price the thesis aimed for
Entry zone
$64.54 – $68.45
the fair-value band we waited for
Price at publication
$68.48
published July 7, 2025
Confidence
85%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Share price has pulled back, giving a chance to buy this leader. The stock is sitting near its longer-term average price, and two big events are coming within three months: expansion into India on July 7 and test results that could widen its heart-health claim. Investor mood is strong, and at 33 times expected profit the shares are 25% cheaper than rival Lilly, leaving space to climb toward $83 by quarter-end.

Primary drivers

  • India launch boosts potential customer base; obesity market grew 5x since 2021
  • Major study results this quarter may let Wegovy claim heart benefits
  • Price sitting on long-term average shows a healthy pullback for new buyers
  • Trades at 33x earnings versus Lilly's 45x, so it has room to close the gap

How it played out

NVO: target not reached by window end

Lyra published NVO at $68.48 on 2025-07-07 with 20% expected growth and a target of $81.26. The thesis pointed to the India launch, possible Wegovy heart-health results, a pullback near the longer-term average, and a valuation of 33 times expected profit versus Lilly's 45 times.

Inside the window, the stock peaked at $71 on 2025-07-25, a 3.7% gain. It stayed below the target and never reached it. By 2025-10-05, it ended at $59.63. The thesis did not play out on price.

What happened during the window

On 2025-07-29, Novo Nordisk lowered its 2025 sales growth outlook to 8-14% and operating profit growth outlook to 10-16%. On 2025-09-10, the company announced a restructuring with 9,000 job cuts, including 5,000 in Denmark.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals